Rosetta Biosoftware Announces the Rosetta Syllego System for Genetic Data Management and Analysis; New Product to be Showcased at Workshop at 11th Annual Human Genome Meeting in Helsinki, Finland

Rosetta Biosoftware announced today the availability of
their new product, the Rosetta Syllego(TM) Genetic Data Management and
Analysis System for genetic studies. The system is designed to
effectively manage genetic data from disparate sources and combine
relevant genotypic and phenotypic study data so that scientists can
spend their time analyzing data and drawing conclusions instead of
contending with data from multiple sources.
"Customers and prospects have shared with us their frustrations
for finding a resource that can capture and store data from a range of
sources, so we designed the Syllego system to address this need. The
system enables researchers to plan and conduct genetic studies using
various commercial genotyping platforms and vendor assays and
integrate relevant study data," said Yelena Shevelenko, vice president
and general manager of Rosetta Biosoftware. "Further, the system
includes quality control tools to prevent loss of time in downstream
analyses as well as automation and project management tools to record
and plan analysis workflows and catalog data for future studies. All
of these tools help scientists spend less time transforming and
formatting data and more time analyzing data."
The Syllego system also includes basic data analysis tools and the
ability to integrate study data with common statistical packages, such
as R. The system will be demonstrated at the Human Genome Organisation
conference in Helsinki, Finland, May 31 - June 3, as well at Rosetta
Biosoftware's upcoming conference, the Rosetta Technology Forum, also
in Helsinki, June 4 - 5. To register for this forum free of charge,
please visit www.rosettabio.com/conferences.

About the Rosetta Syllego System

The Rosetta Syllego system is Rosetta Biosoftware's practical
solution for genetic data management and analysis. Designed for
scientists engaged in genetic studies, such as eQTL or genome-wide
association or linkage, the system is a resource for managing genetic
variation information. The system captures and stores SNP genotyping
assay data and information from leading technology platforms so that
you can better plan and execute genetic studies. QC tools help you
verify that data are high-quality to prevent loss of time in
downstream analyses. Application tools enable you to combine relevant
genotypic and phenotypic study data to interface with the statistical
environment of your choice. And automation tools enable you to analyze
and catalog study data and analysis results, so that you can
incorporate findings into future studies. Because the system is built
upon Rosetta Biosoftware's existing informatics platform, it can
integrate with other Rosetta Biosoftware products, your own in-house
tools, or other third-party platforms. For more information on the
Syllego system, please visit www.rosettabio.com/syllego.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions
for life science research. Its comprehensive software solutions,
including the Rosetta Resolver, Rosetta Elucidator, and Rosetta
Syllego systems, empower life scientists with advanced, scalable, and
easy-to-use analysis platforms that accelerate discovery research.
Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a
wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More
information about Rosetta Biosoftware is available at
www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements involve risks and uncertainties, which may
cause results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, or financial
performance. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Neither
Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation
to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Forward-looking
statements in this press release should be evaluated together with the
many uncertainties that affect the business of Merck & Co., Inc.
including, among others, the extent to which Rosetta Inpharmatics'
technology platform can be used in drug discovery programs,
uncertainty of market acceptance of Rosetta Inpharmatics'
technologies, ability to compete against existing technologies, and
those mentioned in the cautionary statements in Item 1 of Merck's Form
10-K for the year ended Dec. 31, 2005, and in its periodic reports on
Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered
trademarks of Rosetta Inpharmatics LLC. Rosetta Syllego is a trademark
of Rosetta Inpharmatics LLC.